Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case report

BACKGROUND: Trastuzumab (T-mab)-based chemotherapy is a standard regimen for human epithelial growth factor 2 (HER2)-positive gastric cancer. However, some patients have demonstrated a change in HER2 status after T-mab-based treatment of breast cancer. We report a rare case of mixed adenoneuroendocr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagata, Hiromi, Tsujimoto, Hironori, Yaguchi, Yoshihisa, Kouzu, Keita, Itazaki, Yujiro, Ishibashi, Yusuke, Tsuchiya, Satoshi, Sugihara, Takao, Ito, Nozomi, Harada, Manabu, Nomura, Shinsuke, Utsumi, Yoshitaka, Shimazaki, Hideyuki, Kishi, Yoji, Ueno, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949340/
https://www.ncbi.nlm.nih.gov/pubmed/31916037
http://dx.doi.org/10.1186/s40792-020-0774-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949340/
https://www.ncbi.nlm.nih.gov/pubmed/31916037
http://dx.doi.org/10.1186/s40792-020-0774-7

Ejemplares similares